Telehealth Companies Become Insurance Gatekeepers for Obesity Medications

Insurers have begun requiring patients to use specific telehealth companies as a condition for covering GLP-1 medications, the class of obesity drugs that includes Ozempic and Wegovy. The requirement creates a new decision point between doctors, patients, and insurance companies.

David Davis, a power plant worker in Aptos, California, encountered this arrangement when his doctor prescribed a GLP-1 medication to address his obstructive sleep apnea. His insurance company required him to receive care through Vida Health, an online telehealth platform, before approving the prescription.

Telehealth companies frame their role as providing patients with lifestyle support to maximize weight loss results. Vida Health and similar providers offer coaching and monitoring services alongside medication management.

Employers who fund insurance plans have pushed insurers to add these requirements. Employers aim to manage spending on expensive obesity drugs while ensuring that patients who do receive them have support services in place.

The arrangement gives telehealth intermediaries significant authority over medication access. Patients seeking coverage must work through these designated providers rather than obtaining prescriptions directly from their own doctors or other clinicians.

Insurance companies defend the model by noting that telehealth providers can monitor whether patients follow prescribed lifestyle changes and medication protocols. Insurers contend this oversight helps control costs while improving treatment outcomes.

GLP-1 medications have become expensive focal points for health plan spending. A month's supply can cost $1,000 or more before insurance. As demand for the drugs has grown, insurers have implemented prior authorization requirements and other approval steps to manage expenditures.

The telehealth requirement represents an additional gatekeeping layer. Patients must receive approval not only from insurers but also from the designated online provider before accessing coverage.

Critics argue the system creates barriers to medication access for some patients, though insurers maintain it ensures appropriate use. The model remains relatively new, and its long-term effects on patient outcomes and medication costs remain unclear.

Some employers and insurers have adopted the approach, while others continue to cover obesity medications through traditional channels without requiring telehealth intermediaries. Coverage policies vary significantly across health plans and regions.